CL2019001623A1 - Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor. - Google Patents

Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor.

Info

Publication number
CL2019001623A1
CL2019001623A1 CL2019001623A CL2019001623A CL2019001623A1 CL 2019001623 A1 CL2019001623 A1 CL 2019001623A1 CL 2019001623 A CL2019001623 A CL 2019001623A CL 2019001623 A CL2019001623 A CL 2019001623A CL 2019001623 A1 CL2019001623 A1 CL 2019001623A1
Authority
CL
Chile
Prior art keywords
prevent
relieve
carbamate compound
tremor syndrome
treat
Prior art date
Application number
CL2019001623A
Other languages
English (en)
Spanish (es)
Inventor
Jin Uk Yoo
Hye Sung Lee
Han Ju Yi
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of CL2019001623A1 publication Critical patent/CL2019001623A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2019001623A 2016-12-14 2019-06-12 Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor. CL2019001623A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160170225 2016-12-14

Publications (1)

Publication Number Publication Date
CL2019001623A1 true CL2019001623A1 (es) 2019-08-23

Family

ID=62558966

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001623A CL2019001623A1 (es) 2016-12-14 2019-06-12 Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor.

Country Status (13)

Country Link
US (1) US11033531B2 (https=)
EP (1) EP3556364B1 (https=)
JP (1) JP7086076B2 (https=)
KR (1) KR102635941B1 (https=)
CN (1) CN110267657B (https=)
AU (1) AU2017374459B2 (https=)
CL (1) CL2019001623A1 (https=)
ES (1) ES3039979T3 (https=)
IL (1) IL267191B2 (https=)
MX (1) MX391363B (https=)
MY (1) MY198417A (https=)
WO (1) WO2018111009A1 (https=)
ZA (1) ZA201903749B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3711760B1 (en) * 2017-11-14 2024-02-14 SK Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing or treating diseases associated with increase in late sodium current
US20220117941A1 (en) * 2018-09-21 2022-04-21 Sk Biopharmaceuticals Co., Ltd. Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1262272C (zh) 2001-02-27 2006-07-05 奥索-麦克尼尔药品公司 用于预防或治疗运动障碍的氨基甲酸酯化合物
EP1732564A1 (en) 2004-03-29 2006-12-20 Merck & Co., Inc. Biaryl substituted pyrazinones as sodium channel blockers
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
CA2679206C (en) * 2007-03-05 2015-02-24 Indus Biotech Private Limited Pharmaceutical compositions comprising trigonelline and 4-hydroxyisoleucine and a process thereof
PL2445890T3 (pl) 2009-06-22 2016-02-29 Sk Biopharmaceuticals Co Ltd Sposób wytwarzania estru (R)-1-arylo-2-tetrazoliloetylowego kwasu karbaminowego
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
EP2968210B1 (en) 2013-03-12 2024-09-11 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating pediatric epilesy
KR102489052B1 (ko) * 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Also Published As

Publication number Publication date
WO2018111009A1 (ko) 2018-06-21
JP2020502137A (ja) 2020-01-23
MX2019006941A (es) 2019-09-06
CN110267657A (zh) 2019-09-20
RU2019121914A3 (https=) 2021-04-21
IL267191B2 (en) 2023-05-01
IL267191B1 (en) 2023-01-01
ES3039979T3 (en) 2025-10-28
CN110267657B (zh) 2022-12-13
BR112019012000A2 (pt) 2019-10-29
MX391363B (es) 2025-03-21
KR20190087573A (ko) 2019-07-24
IL267191A (https=) 2019-07-31
EP3556364A1 (en) 2019-10-23
RU2019121914A (ru) 2021-01-15
MY198417A (en) 2023-08-29
AU2017374459B2 (en) 2023-04-27
US11033531B2 (en) 2021-06-15
EP3556364B1 (en) 2025-08-27
KR102635941B1 (ko) 2024-02-13
EP3556364A4 (en) 2020-06-17
AU2017374459A1 (en) 2019-07-04
ZA201903749B (en) 2022-01-26
CA3046300A1 (en) 2018-06-21
US20190336481A1 (en) 2019-11-07
JP7086076B2 (ja) 2022-06-17

Similar Documents

Publication Publication Date Title
DOP2019000117A (es) Nuevos derivados de quinolina
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
CL2018002009A1 (es) Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.
UY37789A (es) Nuevos derivados de azaquinolina
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
MX2020004694A (es) Composiciones farmaceuticas inyectables de isoxazolina y su uso contra la infestacion de parasitos.
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2019012522A (es) Compuestos y metodos terapeuticos.
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
PE20161385A1 (es) Formulacion inmunosupresora
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX377172B (es) Formulacion de combinacion de tesofensina y betabloqueante
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2019001623A1 (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor.
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
MX2021004342A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.